JP2006517970A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517970A5
JP2006517970A5 JP2006503521A JP2006503521A JP2006517970A5 JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5 JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
cancer
cancer therapeutic
antibody
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/004116 external-priority patent/WO2004074437A2/en
Publication of JP2006517970A publication Critical patent/JP2006517970A/ja
Publication of JP2006517970A5 publication Critical patent/JP2006517970A5/ja
Pending legal-status Critical Current

Links

JP2006503521A 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法 Pending JP2006517970A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44771403P 2003-02-14 2003-02-14
PCT/US2004/004116 WO2004074437A2 (en) 2003-02-14 2004-02-13 Compositions and methods for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2006517970A JP2006517970A (ja) 2006-08-03
JP2006517970A5 true JP2006517970A5 (cg-RX-API-DMAC7.html) 2007-04-05

Family

ID=32908487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503521A Pending JP2006517970A (ja) 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法

Country Status (5)

Country Link
US (3) US8795672B2 (cg-RX-API-DMAC7.html)
EP (1) EP1599572A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006517970A (cg-RX-API-DMAC7.html)
CA (1) CA2516028C (cg-RX-API-DMAC7.html)
WO (1) WO2004074437A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
CN101072578A (zh) * 2004-10-29 2007-11-14 南加州大学 用共刺激分子的联合癌症免疫疗法
GB0525535D0 (en) * 2005-12-15 2006-01-25 Cgt Corp Tumour treatment
US20090317407A1 (en) * 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
US11071754B2 (en) * 2013-03-11 2021-07-27 Case Western Reserve University Method of generating tumor-specific T cells
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
WO2015058148A1 (en) * 2013-10-17 2015-04-23 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
WO2017184873A2 (en) 2016-04-20 2017-10-26 Aelan Cell Technologies, Inc. Compositions and methods related to the methylation of histone h1.0 protein
US11564944B2 (en) 2016-11-21 2023-01-31 Nant Holdings Ip, Llc Fractal combination therapy
KR20240148849A (ko) * 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JP7252953B2 (ja) 2017-10-25 2023-04-05 エアラン セル テクノロジーズ, インコーポレイテッド H1.0k180me2抗体、その作製および使用の方法
CN112020516B (zh) 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
TW202144429A (zh) 2020-05-14 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗cd25抗體、其抗原結合片段及其醫藥用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) * 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
ATE155482T1 (de) * 1990-04-06 1997-08-15 Jolla Cancer Res Found Verfahren und verbindung zur behandlung von thrombose
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT706799E (pt) * 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5767071A (en) * 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
GB9814383D0 (en) * 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
US6356619B1 (en) * 2000-06-02 2002-03-12 General Electric Company Varying x-ray tube focal spot dimensions to normalize impact temperature
MXPA03006587A (es) * 2001-01-24 2003-09-22 Schering Corp Quimiocinas como adyuvantes de respuesta inmune.
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US20030148982A1 (en) * 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy

Similar Documents

Publication Publication Date Title
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
DeVita et al. The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
US10624973B2 (en) Methods for the depletion of cells
ES2981745T3 (es) Agentes de señalización biespecíficos y usos de los mismos
CA2926698C (en) Chimeric antigen receptor t cell switches and uses thereof
Mack et al. The next generation of antibody drug conjugates
JP2016509582A5 (cg-RX-API-DMAC7.html)
Quiles et al. Synthesis and preliminary biological evaluation of high-drug load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
JP2017507936A5 (cg-RX-API-DMAC7.html)
CA2516028A1 (en) Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
WO2006050172A3 (en) Combination cancer immunotherapy with co-stimulatory molecules
RU2017144606A (ru) Иммуноцитокины на основе il-15 и il-15rа домена sushi
JP2018510132A5 (cg-RX-API-DMAC7.html)
JP2025072462A (ja) 固形および液体悪性病変における多重car t細胞での複数抗原の標的化
JP2012102122A5 (cg-RX-API-DMAC7.html)
AR042977A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
KR20160022370A (ko) 면역요법을 위한 조성물 및 방법
Tian et al. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone
Safdari et al. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies
JP2025527534A (ja) 抗-ヒト表皮成長因子受容体2(her2)キメラ抗原受容体(car)を含むナチュラルキラー細胞を投与する方法
JP2006528627A5 (cg-RX-API-DMAC7.html)
JP2009510165A5 (cg-RX-API-DMAC7.html)
Chen et al. Degrader-drug conjugate (DDC) mediated immunochemotherapy for tumor treatment
US12403200B2 (en) Methods and compositions for treating autoimmune diseases